Tumor necrosis factor-α, biologic agents and cardiovascular risk

Piercarlo Sarzi-Puttini, F. Atzeni, A. Doria, L. Iaccarino, M. Turiel

Research output: Contribution to journalArticle

Abstract

The increased risk of premature cardiovascular disease (CVD) in rheumatoid arthritis (RA) patients may depend on traditional risk factors but may also be attributable to RA-specific risk factors such as disease-related dyslipidemia, or cytokines such as tumor necrosis factor-α (TNF-α). TNF-α is a proinflammatory cytokine that can produce widespread deleterious effects when expressed in large amounts. It is produced in the heart by both cardiac myocytes and resident macrophages under conditions of cardiac stress, and is thought to be responsible for many of the untoward manifestations of cardiac disease. TNF-α may play a role in the triggering and perpetuation of atherosclerosis. Treatment with biologic agents directed against TNF-α has significant clinical benefits in inflammatory diseases such as RA and may be able to reduce cardiovascular risk. The disappointing results of the recent studies to antagonize TNF-α in CVD may have various explanations. However, the effects of TNF-α blockers on incident cases of congestive heart failure (CHF) in RA remains controversial. Due to the lack of evidence of a beneficial effect of anti-TNF-α agents in treatment of CHF, they should not be used to treat patients with New York Heart Association (NYHA) class III or IV heart failure.

Original languageEnglish
Pages (from-to)780-784
Number of pages5
JournalLupus
Volume14
Issue number9
DOIs
Publication statusPublished - 2005

Fingerprint

Biological Factors
Tumor Necrosis Factor-alpha
Rheumatoid Arthritis
Heart Failure
Cardiovascular Diseases
Cytokines
Dyslipidemias
Cardiac Myocytes
Heart Diseases
Atherosclerosis
Macrophages
Therapeutics

Keywords

  • Atherosclerosis
  • Biologic agents
  • Cardiovascular disease
  • Rheumatoid arthritis
  • Tumor necrosis factor-α

ASJC Scopus subject areas

  • Rheumatology
  • Immunology

Cite this

Sarzi-Puttini, P., Atzeni, F., Doria, A., Iaccarino, L., & Turiel, M. (2005). Tumor necrosis factor-α, biologic agents and cardiovascular risk. Lupus, 14(9), 780-784. https://doi.org/10.1191/0961203305lu2220oa

Tumor necrosis factor-α, biologic agents and cardiovascular risk. / Sarzi-Puttini, Piercarlo; Atzeni, F.; Doria, A.; Iaccarino, L.; Turiel, M.

In: Lupus, Vol. 14, No. 9, 2005, p. 780-784.

Research output: Contribution to journalArticle

Sarzi-Puttini, P, Atzeni, F, Doria, A, Iaccarino, L & Turiel, M 2005, 'Tumor necrosis factor-α, biologic agents and cardiovascular risk', Lupus, vol. 14, no. 9, pp. 780-784. https://doi.org/10.1191/0961203305lu2220oa
Sarzi-Puttini, Piercarlo ; Atzeni, F. ; Doria, A. ; Iaccarino, L. ; Turiel, M. / Tumor necrosis factor-α, biologic agents and cardiovascular risk. In: Lupus. 2005 ; Vol. 14, No. 9. pp. 780-784.
@article{51d144d1b547489cbb575da7cd7810c5,
title = "Tumor necrosis factor-α, biologic agents and cardiovascular risk",
abstract = "The increased risk of premature cardiovascular disease (CVD) in rheumatoid arthritis (RA) patients may depend on traditional risk factors but may also be attributable to RA-specific risk factors such as disease-related dyslipidemia, or cytokines such as tumor necrosis factor-α (TNF-α). TNF-α is a proinflammatory cytokine that can produce widespread deleterious effects when expressed in large amounts. It is produced in the heart by both cardiac myocytes and resident macrophages under conditions of cardiac stress, and is thought to be responsible for many of the untoward manifestations of cardiac disease. TNF-α may play a role in the triggering and perpetuation of atherosclerosis. Treatment with biologic agents directed against TNF-α has significant clinical benefits in inflammatory diseases such as RA and may be able to reduce cardiovascular risk. The disappointing results of the recent studies to antagonize TNF-α in CVD may have various explanations. However, the effects of TNF-α blockers on incident cases of congestive heart failure (CHF) in RA remains controversial. Due to the lack of evidence of a beneficial effect of anti-TNF-α agents in treatment of CHF, they should not be used to treat patients with New York Heart Association (NYHA) class III or IV heart failure.",
keywords = "Atherosclerosis, Biologic agents, Cardiovascular disease, Rheumatoid arthritis, Tumor necrosis factor-α",
author = "Piercarlo Sarzi-Puttini and F. Atzeni and A. Doria and L. Iaccarino and M. Turiel",
year = "2005",
doi = "10.1191/0961203305lu2220oa",
language = "English",
volume = "14",
pages = "780--784",
journal = "Lupus",
issn = "0961-2033",
publisher = "SAGE Publications Ltd",
number = "9",

}

TY - JOUR

T1 - Tumor necrosis factor-α, biologic agents and cardiovascular risk

AU - Sarzi-Puttini, Piercarlo

AU - Atzeni, F.

AU - Doria, A.

AU - Iaccarino, L.

AU - Turiel, M.

PY - 2005

Y1 - 2005

N2 - The increased risk of premature cardiovascular disease (CVD) in rheumatoid arthritis (RA) patients may depend on traditional risk factors but may also be attributable to RA-specific risk factors such as disease-related dyslipidemia, or cytokines such as tumor necrosis factor-α (TNF-α). TNF-α is a proinflammatory cytokine that can produce widespread deleterious effects when expressed in large amounts. It is produced in the heart by both cardiac myocytes and resident macrophages under conditions of cardiac stress, and is thought to be responsible for many of the untoward manifestations of cardiac disease. TNF-α may play a role in the triggering and perpetuation of atherosclerosis. Treatment with biologic agents directed against TNF-α has significant clinical benefits in inflammatory diseases such as RA and may be able to reduce cardiovascular risk. The disappointing results of the recent studies to antagonize TNF-α in CVD may have various explanations. However, the effects of TNF-α blockers on incident cases of congestive heart failure (CHF) in RA remains controversial. Due to the lack of evidence of a beneficial effect of anti-TNF-α agents in treatment of CHF, they should not be used to treat patients with New York Heart Association (NYHA) class III or IV heart failure.

AB - The increased risk of premature cardiovascular disease (CVD) in rheumatoid arthritis (RA) patients may depend on traditional risk factors but may also be attributable to RA-specific risk factors such as disease-related dyslipidemia, or cytokines such as tumor necrosis factor-α (TNF-α). TNF-α is a proinflammatory cytokine that can produce widespread deleterious effects when expressed in large amounts. It is produced in the heart by both cardiac myocytes and resident macrophages under conditions of cardiac stress, and is thought to be responsible for many of the untoward manifestations of cardiac disease. TNF-α may play a role in the triggering and perpetuation of atherosclerosis. Treatment with biologic agents directed against TNF-α has significant clinical benefits in inflammatory diseases such as RA and may be able to reduce cardiovascular risk. The disappointing results of the recent studies to antagonize TNF-α in CVD may have various explanations. However, the effects of TNF-α blockers on incident cases of congestive heart failure (CHF) in RA remains controversial. Due to the lack of evidence of a beneficial effect of anti-TNF-α agents in treatment of CHF, they should not be used to treat patients with New York Heart Association (NYHA) class III or IV heart failure.

KW - Atherosclerosis

KW - Biologic agents

KW - Cardiovascular disease

KW - Rheumatoid arthritis

KW - Tumor necrosis factor-α

UR - http://www.scopus.com/inward/record.url?scp=26244456758&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=26244456758&partnerID=8YFLogxK

U2 - 10.1191/0961203305lu2220oa

DO - 10.1191/0961203305lu2220oa

M3 - Article

C2 - 16218487

AN - SCOPUS:26244456758

VL - 14

SP - 780

EP - 784

JO - Lupus

JF - Lupus

SN - 0961-2033

IS - 9

ER -